Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATTAIN-HYPERTENSION: Orforglipron in Hypertension with Obesity or Overweight
jRCT2031250164Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2025
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial of orforglipron in hypertension (HTN), obesity and Overweight (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants Allocated to Each ISA. Started Jun 2025; status: active, not recruiting.
02
Drugs
orforglipron
03
Conditions
hypertension (HTN)obesityOverweight
Beyond the preview
Go deeper on jRCT2031250164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250164.